CLINICAL TRIALS PROFILE FOR AMINOGLUTETHIMIDE

All Clinical Trials for AMINOGLUTETHIMIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	Janssen Pharmaceuticals	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
NCT00006371 ↗	A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer	Terminated	H. Lee Moffitt Cancer Center and Research Institute	Phase 2	2000-05-01	RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones. Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate cancer.
NCT00134680 ↗	Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	Completed	Genentech, Inc.	Phase 2	2000-01-01	The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®) has on breast cancer. The United States (US) Food and Drug Administration has approved both letrozole and Herceptin for the treatment of advanced breast cancer. Doctors hope that the combination will work better than either drug alone.

Clinical Trial Conditions for AMINOGLUTETHIMIDE

Condition Name

Condition Name for AMINOGLUTETHIMIDE
Intervention	Trials
Adrenocortical Carcinoma	2
Peritoneal Carcinomatosis	2
Atrial Fibrillation	1
Early-stage Breast Cancer	1

Condition MeSH

Condition MeSH for AMINOGLUTETHIMIDE
Intervention	Trials
Peritoneal Neoplasms	2
Carcinoma	2
Adrenocortical Carcinoma	2
Breast Neoplasms	2

Clinical Trial Locations for AMINOGLUTETHIMIDE

Trials by Country

Trials by Country for AMINOGLUTETHIMIDE
Location	Trials
United States	7
Brazil	1

Trials by US State

Trials by US State for AMINOGLUTETHIMIDE
Location	Trials
New York	1
Maryland	1
North Carolina	1
Missouri	1
Massachusetts	1

Clinical Trial Progress for AMINOGLUTETHIMIDE

Clinical Trial Phase

Clinical Trial Phase for AMINOGLUTETHIMIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for AMINOGLUTETHIMIDE
Clinical Trial Phase	Trials
Completed	4
Recruiting	1
Terminated	1

Clinical Trial Sponsors for AMINOGLUTETHIMIDE

Sponsor Name

Sponsor Name for AMINOGLUTETHIMIDE
Sponsor	Trials
National Cancer Institute (NCI)	2
Columbia University	1
Janssen Pharmaceuticals	1

Sponsor Type

Sponsor Type for AMINOGLUTETHIMIDE
Sponsor	Trials
Other	6
Industry	4
NIH	2